國立高雄大學圖資館 |

Language: English

Back

Lasso peptidesbacterial strategies t...

Li, Yanyan.

Lasso peptidesbacterial strategies to make and maintain bioactive entangled scaffolds /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Lasso peptidesby Yanyan Li, Severine Zirah, Sylvie Rebuffat.
Reminder of title:	bacterial strategies to make and maintain bioactive entangled scaffolds /
Author:	Li, Yanyan.
other author:	Zirah, Severine.
Published:	New York, NY :Springer New York :2015.
Description:	xiii, 103 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Peptides.
Online resource:	http://dx.doi.org/10.1007/978-1-4939-1010-6
ISBN:	9781493910106 (electronic bk.)

Lasso peptidesbacterial strategies to make and maintain bioactive entangled scaffolds /
Li, Yanyan.

Lasso peptidesbacterial strategies to make and maintain bioactive entangled scaffolds /[electronic resource] :by Yanyan Li, Severine Zirah, Sylvie Rebuffat. - New York, NY :Springer New York :2015. - xiii, 103 p. :ill. (some col.), digital ;24 cm. - SpringerBriefs in microbiology,2191-5385. - SpringerBriefs in microbiology..

Overview on Lasso Peptide Research -- From the Producer Microorganisms to the Lasso Scaffold -- Biological Activities of Lasso Peptides and Structure-Activity Relationships -- Biosynthesis, Regulation and Export of Lasso Peptides -- Lasso Peptide Bioengineering and Bioprospecting.

Lasso peptides form a growing family of fascinating ribosomally-synthesized and post-translationally modified peptides produced by bacteria. They contain 15 to 24 residues and share a unique interlocked topology that involves an N-terminal 7 to 9-residue macrolactam ring where the C-terminal tail is threaded and irreversibly trapped. The ring results from the condensation of the N-terminal amino group with a side-chain carboxylate of a glutamate at position 8 or 9, or an aspartate at position 7, 8 or 9. The trapping of the tail involves bulky amino acids located in the tail below and above the ring and/or disulfide bridges connecting the ring and the tail. Lasso peptides are subdivided into three subtypes depending on the absence (class II) or presence of one (class III) or two (class I) disulfide bridges. The lasso topology results in highly compact structures that give to lasso peptides an extraordinary stability towards both protease degradation and denaturing conditions. Lasso peptides are generally receptor antagonists, enzyme inhibitors and/or antibacterial or antiviral (anti-HIV) agents. The lasso scaffold and the associated biological activities shown by lasso peptides on different key targets make them promising molecules with high therapeutic potential. Their application in drug design has been exemplified by the development of an integrin antagonist based on a lasso peptide scaffold. The biosynthesis machinery of lasso peptides is therefore of high biotechnological interest, especially since such highly compact and stable structures have to date revealed inaccessible by peptide synthesis. Lasso peptides are produced from a linear precursor LasA, which undergoes a maturation process involving several steps, in particular cleavage of the leader peptide and cyclization. The post-translational modifications are ensured by a dedicated enzymatic machinery, which is composed of an ATP-dependent cysteine protease (LasB) and a lactam synthetase (LasC) that form an enzymatic complex called lasso synthetase. Microcin J25, produced by Escherichia coli AY25, is the archetype of lasso peptides and the most extensively studied. To date only around forty lasso peptides have been isolated, but genome mining approaches have revealed that they are widely distributed among Proteobacteria and Actinobacteria, particularly in Streptomyces, making available a rich resource of novel lasso peptides and enzyme machineries towards lasso topologies.

ISBN: 9781493910106 (electronic bk.)

Standard No.: 10.1007/978-1-4939-1010-6doiSubjects--Topical Terms:

202659
Peptides.

LC Class. No.: QP552.P4

Dewey Class. No.: 572.65

Lasso peptidesbacterial strategies to make and maintain bioactive entangled scaffolds /
LDR:03836nmm a2200325 a 4500 001 459952
003 DE-He213
005 20150609115308.0
006 m d
007 cr nn 008maaau
008 151110s2015 nyu s 0 eng d
020 $a 9781493910106 (electronic bk.)
020 $a 9781493910090 (paper)
024 7 $a 10.1007/978-1-4939-1010-6 $2 doi
035 $a 978-1-4939-1010-6
040 $a GP $c GP
041 0 $a eng
050 4 $a QP552.P4
072 7 $a MMFM $2 bicssc
072 7 $a MED052000 $2 bisacsh
082 0 4 $a 572.65 $2 23
090 $a QP552.P4 $b L693 2015
100 1 $a Li, Yanyan. $3 710892
245 1 0 $a Lasso peptides $h [electronic resource] : $b bacterial strategies to make and maintain bioactive entangled scaffolds / $c by Yanyan Li, Severine Zirah, Sylvie Rebuffat.
260 $a New York, NY : $b Springer New York : $b Imprint: Springer, $c 2015.
300 $a xiii, 103 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a SpringerBriefs in microbiology, $x 2191-5385
505 0 $a Overview on Lasso Peptide Research -- From the Producer Microorganisms to the Lasso Scaffold -- Biological Activities of Lasso Peptides and Structure-Activity Relationships -- Biosynthesis, Regulation and Export of Lasso Peptides -- Lasso Peptide Bioengineering and Bioprospecting.
520 $a Lasso peptides form a growing family of fascinating ribosomally-synthesized and post-translationally modified peptides produced by bacteria. They contain 15 to 24 residues and share a unique interlocked topology that involves an N-terminal 7 to 9-residue macrolactam ring where the C-terminal tail is threaded and irreversibly trapped. The ring results from the condensation of the N-terminal amino group with a side-chain carboxylate of a glutamate at position 8 or 9, or an aspartate at position 7, 8 or 9. The trapping of the tail involves bulky amino acids located in the tail below and above the ring and/or disulfide bridges connecting the ring and the tail. Lasso peptides are subdivided into three subtypes depending on the absence (class II) or presence of one (class III) or two (class I) disulfide bridges. The lasso topology results in highly compact structures that give to lasso peptides an extraordinary stability towards both protease degradation and denaturing conditions. Lasso peptides are generally receptor antagonists, enzyme inhibitors and/or antibacterial or antiviral (anti-HIV) agents. The lasso scaffold and the associated biological activities shown by lasso peptides on different key targets make them promising molecules with high therapeutic potential. Their application in drug design has been exemplified by the development of an integrin antagonist based on a lasso peptide scaffold. The biosynthesis machinery of lasso peptides is therefore of high biotechnological interest, especially since such highly compact and stable structures have to date revealed inaccessible by peptide synthesis. Lasso peptides are produced from a linear precursor LasA, which undergoes a maturation process involving several steps, in particular cleavage of the leader peptide and cyclization. The post-translational modifications are ensured by a dedicated enzymatic machinery, which is composed of an ATP-dependent cysteine protease (LasB) and a lactam synthetase (LasC) that form an enzymatic complex called lasso synthetase. Microcin J25, produced by Escherichia coli AY25, is the archetype of lasso peptides and the most extensively studied. To date only around forty lasso peptides have been isolated, but genome mining approaches have revealed that they are widely distributed among Proteobacteria and Actinobacteria, particularly in Streptomyces, making available a rich resource of novel lasso peptides and enzyme machineries towards lasso topologies.
650 0 $a Peptides. $3 202659
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Medical Microbiology. $3 273931
650 2 4 $a Immunology. $3 189152
650 2 4 $a Vaccine. $3 337782
700 1 $a Zirah, Severine. $3 711032
700 1 $a Rebuffat, Sylvie. $3 511458
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a SpringerBriefs in microbiology. $3 559438
856 4 0 $u http://dx.doi.org/10.1007/978-1-4939-1010-6
950 $a Biomedical and Life Sciences (Springer-11642)